No Data
No Data
No Data
No Data
No Data
Spruce Biosciences to Participate in May Investor Conferences
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced
BusinesswireMay 2 04:05
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Presentation to highlight baseline characteristics of Spruce's CAHptain program evaluating tildacerfont in pediatric congenital adrenal hyperplasia (CAH)The company is also highlighting baseline chara
BusinesswireMay 1 04:05
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Presentation to highlight baseline characteristics of Spruce's CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease
BusinesswireApr 23 04:05
Spruce Biosciences(SPRB.US) 10% Shareholder Sells US$350.95K in Common Stocks
$Spruce Biosciences(SPRB.US)$ 10% Shareholder Novo Holdings A/S sold 465.02K shares of Common Stocks on Mar 21, 2024 at an average price of $0.7547 for a total value of $350.95K.Source: Announcement W
Futu NewsMar 26 10:28
Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)
Yahoo FinanceMar 23 20:47
Spruce Biosciences(SPRB.US) 10% Shareholder Sells US$1.36 Million in Common Stocks
$Spruce Biosciences(SPRB.US)$ 10% Shareholder Novo Holdings A/S sold 1.79 million shares of Common Stocks on Mar 18, 19, 20, 2024 at an average price of $0.757 for a total value of $1.36 million.Sourc
Futu NewsMar 21 09:36
No Data
No Data